Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Netherlands Heart Journal
Published in: Netherlands Heart Journal 9/2017

Open Access 01-09-2017 | Review Article

Carcinoid heart disease: a guide for screening and timing of surgical intervention

Authors: E. A. Hart, T. A. Meijs, R. C. A. Meijer, K. M. Dreijerink, M. E. Tesselaar, C. A. de Groot, G. D. Valk, S. A. J. Chamuleau

Published in: Netherlands Heart Journal | Issue 9/2017

Login to get access

Abstract

The cardiac manifestations of a neuroendocrine tumour are referred to as carcinoid heart disease (CaHD) and are associated with a poor prognosis. Surgical intervention is the only proven therapeutic option and may prolong survival and quality of life. No consensus has been reached internationally with regard to screening for CaHD and the optimal timing for surgery. Although limited evidence is available on this matter, a trend towards early surgery and subsequent reduced mortality has been observed. In this review we provide an overview of the current understanding and propose a protocol to guide cardiologists in the screening for CaHD and the timing of referral to a specialised surgical centre.
Literature
1.
Yao JC, Hassan M, Phan A, et al. One hundred years after ‘carcinoid’: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72.CrossRefPubMed
2.
Hauso O, Gustafsson BI, Kidd M, et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer. 2008;113:2655–64.CrossRefPubMed
3.
Modlin IM, Kidd M, Latich I, et al. Current status of gastrointestinal carcinoids. Gastroenterology. 2005;128:1717–51.CrossRefPubMed
4.
Grozinsky-Glasberg S, Grossman AB, Gross DJ. Carcinoid heart disease: from pathophysiology to treatment – ’something in the way it moves’. Neuroendocrinology. 2015;101:263–73.CrossRefPubMed
5.
6.
Pellikka PA, Tajik AJ, Khandheria BK, et al. Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients. Circulation. 1993;87:1188–96.CrossRefPubMed
7.
Bhattacharyya S, Toumpanakis C, Chilkunda D, et al. Risk factors for the development and progression of carcinoid heart disease. Am J Cardiol. 2011;107:1221–6.CrossRefPubMed
8.
Zuetenhorst J, Bonfrer J, Korse C, et al. Carcinoid heart disease: the role of urinary 5‑hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor-beta and fibroblast growth factor. Cancer. 2003;97:1609–15.CrossRefPubMed
9.
Bhattacharyya S, Toumpanakis C, Caplin ME, et al. Analysis of 150 patients with carcinoid syndrome seen in a single year at one institution in the first decade of the twenty-first century. Am J Cardiol. 2008;101:378–81.CrossRefPubMed
10.
Pandya UH, Pellikka PA, Enriquez-Sarano M, et al. Metastatic carcinoid tumor to the heart: Echocardiographic-pathologic study of 11 patients. J Am Coll Cardiol. 2002;40:1328–32.CrossRefPubMed
11.
Greminger P, Hess OM, Müller AE, et al. Bronchial neuroendocrine (carcinoid) tumor causing unilateral left-sided carcinoid heart disease. Klin Wochenschr. 1991;69:128–33.CrossRefPubMed
12.
Marupakula V, Vinales KL, Najib MQ, et al. Occurrence of left-sided heart valve involvement before right-sided heart valve involvement in carcinoid heart disease. Eur J Echocardiogr. 2011;12(3):E18.PubMed
13.
Møller JE, Connolly HM, Rubin J, et al. Factors associated with progression of carcinoid heart disease. N Engl J Med. 2003;348:1005–15.CrossRefPubMed
14.
Dobson R, Burgess MI, Pritchard DM, et al. The clinical presentation and management of carcinoid heart disease. Int J Cardiol. 2014;173:29–32.CrossRefPubMed
15.
Ross EM, Roberts WC. The carcinoid syndrome: Comparison of 21 necropsy subjects with carcinoid heart disease to 15 necropsy subjects without carcinoid heart disease. Am J Med. 1985;79:339–54.CrossRefPubMed
16.
Bhattacharyya S, Toumpanakis C, Caplin ME, et al. Usefulness of N‑terminal pro-brain Natriuretic peptide as a Biomarker of the presence of Carcinoid heart disease. Am J Cardiol. 2008;102:938–42.CrossRefPubMed
17.
Vinik AI, Woltering EA, Warner RR, et al. NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas. 2010;39:713–34.CrossRefPubMed
18.
Dobson R, Burgess MI, Valle JW, et al. Serial surveillance of carcinoid heart disease: factors associated with echocardiographic progression and mortality. Br J Cancer. 2014;111:1703–9.CrossRefPubMedPubMedCentral
19.
Pape UF, Perren A, Niederle B, et al. ENETS consensus guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology. 2012;95:135–56.CrossRefPubMed
20.
Robiolio PA, Rigolin VH, Harrison JK, et al. Predictors of outcome of tricuspid valve replacement in carcinoid heart disease. Am J Cardiol. 1995;75:485–8.CrossRefPubMed
21.
Plöckinger U, Gustafsson B, Ivan D, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: Echocardiography. Neuroendocrinology. 2009;90:190–3.CrossRefPubMed
22.
Luis SA, Pellikka PA. Carcinoid heart disease: diagnosis and management. Best Pract Res Clin Endocrinol Metab. 2016;30:149–58.CrossRefPubMed
23.
Haugaa KH, Bergestuen DS, Sahakyan LG, et al. Evaluation of right ventricular dysfunction by myocardial strain echocardiography in patients with intestinal carcinoid disease. J Am Soc Echocardiogr. 2011;24:644–50.CrossRefPubMed
24.
Mansencal N, McKenna WJ, Mitry E, et al. Comparison of prognostic value of tissue doppler imaging in Carcinoid heart disease versus the value in patients with the Carcinoid syndrome but without Carcinoid heart disease. Am J Cardiol. 2010;105:527–31.CrossRefPubMed
25.
Dobson R, Cuthbertson DJ, Burgess MI. The optimal use of cardiac imaging in the quantification of carcinoid heart disease. Endocr Relat Cancer. 2013;20(5):E247.CrossRef
26.
Bousquet C, Lasfargues C, Chalabi M, et al. Current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy. J Clin Endocrinol Metab. 2012;97:727–37.CrossRefPubMed
27.
Rinke A, Müller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group. J Clin Oncol. 2009;27:4656–63.CrossRefPubMed
28.
Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic Enteropancreatic Neuroendocrine tumors. N Engl J Med. 2014;371:224–33.CrossRefPubMed
29.
Kulke MH, O’Dorisio T, Phan A, et al. Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide. Endocr Relat Cancer. 2014;21:705–14.CrossRefPubMedPubMedCentral
30.
Wolin EM, Jarzab B, Eriksson B, et al. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. Drug Des Devel Ther. 2015;9:5075–86.CrossRefPubMedPubMedCentral
31.
Kunz PL. Carcinoid and neuroendocrine tumors: building on success. J Clin Oncol. 2015;33:1855–63.CrossRefPubMed
32.
Bushnell DL, O’Dorisio TM, O’Dorisio MS, et al. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol. 2010;28:1652–9.CrossRefPubMedPubMedCentral
33.
Kwekkeboom DJ, De Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177Lu- DOTA0,Tyr3] octreotate: Toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124–30.CrossRefPubMed
34.
Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017;376:125–35.CrossRefPubMed
35.
Yao JC, Pavel M, Lombard-Bohas C, et al. Everolimus for the treatment of advanced pancreatic Neuroendocrine tumors: overall survival and circulating biomarkers from the randomized, phase III RADIANT-3 study. J Clin Oncol. 2016;34:3906–13.CrossRef
36.
Raymong E, Dahan L, Raoul J, et al. Sunitinib Malate for the treatment of pancreatic Neuroendocrine tumors. N Engl J Med. 2011;364:501–13.CrossRef
37.
Pavel M, Baudin E, Couvelard A, et al. ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95:157–76.CrossRefPubMed
38.
Lillegard JB, Fisher JE, McKenzie TJ, et al. Hepatic resection for the carcinoid syndrome in patients with severe carcinoid heart disease: does valve replacement permit safe hepatic resection? J Am Coll Surg. 2011;213:130–6.CrossRefPubMed
39.
Connolly HM, Schaff HV, Abel MD, et al. Early and late outcomes of surgical treatment in carcinoid heart disease. J Am Coll Cardiol. 2015;66:2189–96.CrossRefPubMed
40.
Connolly HM, Nishimura RA, Smith HC, et al. Outcome of cardiac surgery for carcinoid heart disease. J Am Coll Cardiol. 1995;25:410–6.CrossRefPubMed
41.
Møller JE, Pellikka PA, Bernheim AM, et al. Prognosis of carcinoid heart disease: analysis of 200 cases over two decades. Circulation. 2005;112:3320–7.CrossRefPubMed
42.
Mokhles P, van Herwerden LA, de Jong PL, et al. Carcinoid heart disease: outcomes after surgical valve replacement. Eur J Cardiothorac Surg. 2012;41:1278–83.CrossRefPubMed
43.
Castillo JG, Filsoufi F, Rahmanian PB, et al. Early and late results of valvular surgery for Carcinoid heart disease. J Am Coll Cardiol. 2008;51:1507–9.CrossRefPubMed
44.
Edwards NC, Yuan M, Nolan O, et al. Effect of valvular surgery in carcinoid heart disease: An observational cohort study. J Clin Endocrinol Metab. 2016;101:183–90.CrossRefPubMed
45.
46.
Carrilho-Ferreira P, Silva D, Almeida AG, et al. Carcinoid heart disease: outcome after balloon pulmonary Valvuloplasty. Can J Cardiol. 2013;29(751):e7–751.e9.
47.
Grant SC, Scarffe JH, Levy RD, et al. Failure of balloon dilatation of the pulmonary valve in carcinoid pulmonary stenosis. Br Heart J. 1992;67:450–3.CrossRefPubMedPubMedCentral
48.
Castillo JG, Silvay G, Solís J. Current concepts in diagnosis and perioperative management of carcinoid heart disease. Semin Cardiothorac Vasc Anesth. 2013;17:212–23.CrossRefPubMed
49.
Weingarten TN, Abel MD, Connolly HM, et al. Intraoperative management of patients with carcinoid heart disease having valvular surgery: A review of one hundred consecutive cases. Anesth Analg. 2007;105:1192–9.CrossRefPubMed
50.
Regner KR, Connolly HM, Schaff HV, et al. Acute renal failure after cardiac surgery for carcinoid heart disease: Incidence, risk factors, and prognosis. Am J Kidney Dis. 2005;45:826–32.CrossRefPubMed
51.
Silaschi M, Barr J, Chaubey S, et al. Optimized outcomes using a standardized approach for treatment of patients with Carcinoid heart disease. Neuroendocrinology. 2016;104(3):257–63.CrossRefPubMed
52.
Mota JM, Sousa LG, Riechelmann RP. Complications from carcinoid syndrome: review of the current evidence. Ecancermedicalscience. 2016;10:1–17.CrossRef
53.
Ramage JK, Ahmed A, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut. 2012;61:6–32.CrossRefPubMed
54.
Metadata
Title
Carcinoid heart disease: a guide for screening and timing of surgical intervention
Authors
E. A. Hart
T. A. Meijs
R. C. A. Meijer
K. M. Dreijerink
M. E. Tesselaar
C. A. de Groot
G. D. Valk
S. A. J. Chamuleau
Publication date
01-09-2017
Publisher
Bohn Stafleu van Loghum
Published in
Netherlands Heart Journal / Issue 9/2017
Print ISSN: 1568-5888
Electronic ISSN: 1876-6250
DOI
https://doi.org/10.1007/s12471-017-1011-2

Other articles of this Issue 9/2017

Netherlands Heart Journal 9/2017 Go to the issue

Editor’s Comment

Three decades of heart transplantation in the Netherlands

Original Article - Design Study Article

Is there an alternative treatment for patients intolerant to antiplatelet therapy if percutaneous left atrial appendage closure is considered?

Letter to the Editor

Aortic dissection, a diagnostic challenge

Rhythm Puzzle - Answer

Adequate sensing of ventricular fibrillation?

Letter to the Editor

Fever as a first manifestation of acute aortic dissection

Original Article

Perioperative management of antiplatelet treatment in patients undergoing isolated coronary artery bypass grafting in Dutch cardiothoracic centres

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits